Please login to the form below
isotretinoin
This page shows the latest isotretinoin news and features for those working in and with pharma, biotech and healthcare.
LEO Pharma to acquire Timber Pharmaceuticals in deal worth up to $36m
The transaction will give LEO access to Timber’s lead investigational product candidate, TMB-001, a topical reformulation of isotretinoin to treat the rare skin disease congenital ichthyosis. ... Isotretinoin is an active pharmaceutical ingredient (API)
Latest news
-
Recordati snaps up Swiss pharma company Pro Farma
The firm sealed a deal with independent family-owned Swiss firm Pro Farma last week that was valued at CHF16m and will add to its portfolio the acne treatment Tretinac (isotretinoin)
-
Therapy focus: acne
Severe Acne drug. Now, there is a whole host of drugs, including the contraceptive pill and many herbal remedies, but one that has courted particular attention is isotretinoin (Roaccutane and Accutane), ... Treatment with this drug has had a high success
-
Alliance Pharma's profit up 17 per cent
The products include acne treatment Rizuderm (isotretinoin). The move follows previous acquisitions for Alliance this year, including the pain relief therapy Anbesol (benzocaine).
-
Roche drug slapped with caveats
The Food and Drug Administration (FDA) said it had approved a strengthened distribution programme for Accutane, also known under its generic name isotretinoin, requiring doctors and patients to register and accept
-
News in brief, April 04, 2007
The FDA is launching a special webpage to warn consumers about the dangers of buying Accutane (isotretinoin) online.
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
The product contains isotretinoin (Roaccutane) and has Orphan Drug Designation in the US. ... 50. Patagonia/ Almirall. PAT-001 (isotretinoin-based treatment) – congenital ichthyosis. Licence. 28.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
